Personalized Medicine for Advanced Biliary Cancer Patients
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The object of this trial is to evaluate whether the introduction of a targeted therapy after
4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to
continuing with the standard treatment.
The trial is composed of two phases: (i) An initial screening phase to identify a suitable
patient population, during which a molecular profile of the patient's tumour will be
obtained, and (ii) a randomised comparative trial in which patients with disease control
after 4 cycles of standard treatment, and whose tumour harbours a targetable molecular
alteration, will be randomised (2:1) to receive either a matched targeted therapy or to
continue with the standard treatment.
Phase:
Phase 3
Details
Lead Sponsor:
UNICANCER
Collaborators:
Accord Healthcare, Inc. Belgian Group of Digestive Oncology Cancer Research UK Cancer Research UK & UCL Cancer Trials Centre GlaxoSmithKline Research & Development Limited National Cancer Institute, France Pierre Fabre Medicament Servier Taiho Oncology, Inc. Zymeworks Inc.